OBJECTIVES : Budget impact evaluation of cholesterol level decreasing in the Russian population of patients with Cardio Vascular Diseases (CVD).

METHODS : Population attributive risk of hypercholesterolemia (HCE) was used for evaluation of the share of CVD incidence/mortality/costs, based on official statistics and epidemiological data. Total economic burden was estimated regarding direct (medical and non-medical) and indirect costs. Social and economic effectiveness of (Choletesterol-LDL) СS-LDL decrease by 1 mmol/l among patients with СVD, including health care system economy and reduction of economic losses were estimated, taking into account primary/recurring PCI.

RESULTS : GDP losses due to premature mortality in economically active age from diseases associated with HCE with the lack of lipid lowering treatment (or without it) is expected as $505 bln for ischemic cardiac disease and $303 bln. for other circulatory illnesses annually. Lowering effect of CS-LDL by 1 mmol/l (during a year) is: outpatient care cost can decrease more than in 3 times for Ischemic Cardiac Disease (IHD) and in 5 times for Stroke that lead to decrease of budget impact in 3,8 and 5,0 times accordingly. Hospital admission is expected to be in 4,5-5 times less. Under the current rate of performing of PCI, the reduction of CS-LDL by 1 mmol/l enables to reduce the number of PCI by 20% annually. It will reduce the annual expenditures on this kind of treatment by almost 5 times or ~$113 mln annually). Decrease CS-LDL by 1 mmol/l can save ~$1,59 bln. due to less myocardial infarction, ~$1,32 bln. for strokes. On a national level the decrease of expenditures and losses in the economy which are analysed will make up ~$9,65 bln. (~0,7% of GDP).

CONCLUSIONS : Decrease of CS-LDL for patients with CVD has economic effect on health care system and can lead to decrease of budget impact and has social humanitarian effects.